8-KOther EventsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 13, 2012)

Filed February 13, 2012For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) announced the successful completion of its acquisition of Inhibitex, Inc. on February 13, 2012. This acquisition was executed as a two-step transaction, commencing with a cash tender offer for Inhibitex shares at $26.00 per share, followed by a merger. The company's wholly-owned subsidiary, Inta Acquisition Corporation, managed the tender offer, ensuring all outstanding shares not already owned by BMY and its subsidiaries were acquired. This strategic move signifies BMY's commitment to expanding its portfolio, likely through the integration of Inhibitex's assets or pipeline. Investors should monitor how this acquisition impacts BMY's future product development, research and development investments, and overall market position, particularly in areas where Inhibitex held expertise.

Key Highlights

  • 1Bristol-Myers Squibb (BMY) has completed the acquisition of Inhibitex, Inc.
  • 2The acquisition was a two-step transaction, including a cash tender offer.
  • 3The tender offer price was $26.00 per share for Inhibitex common stock.
  • 4BMY's subsidiary, Inta Acquisition Corporation, facilitated the tender offer.
  • 5The transaction aimed to acquire all outstanding Inhibitex shares not already owned by BMY or its subsidiaries.
  • 6The acquisition was officially announced on February 13, 2012.

Frequently Asked Questions

The primary purpose of this 8-K filing was to announce the completion of Bristol-Myers Squibb's acquisition of Inhibitex, Inc.

The cash tender offer for Inhibitex, Inc. was priced at $26.00 per share, net to the seller in cash.

The acquisition was structured as a two-step transaction. It began with a cash tender offer by BMY's subsidiary, Inta Acquisition Corporation, for Inhibitex shares, followed by a merger of Inta Acquisition Corporation with and into Inhibitex.

This acquisition indicates BMY's strategic intent to grow its business, likely by integrating Inhibitex's assets, technology, or drug pipeline into its existing operations. Investors should look for further announcements regarding the impact on BMY's R&D efforts and product portfolio.